Details of the Drug Reposition

General Information of This Drug (ID: DMIXC7G)

Drug Name
Zoledronate   DMIXC7G
Synonyms
Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
Therapeutic Class
Bone Density Conservation Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bone Paget disease DISIPS4V N.A. Approved [1]
Bone giant cell tumor DIS0RGK9 N.A. Approved [2]
Adenocarcinoma DIS3IHTY 2D40 Approved [3]
Hypercalcaemia DISKQ2K7 5B91.0 Approved [4]
Multiple sclerosis DISB2WZI 8A40 Approved [5]
Osteoporosis DISF2JE0 FB83.0 Approved [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Humoral hypercalcemia of malignancy DISQQ62D N.A. Discontinued in Phase 1 [7]
------------------------------------------------------------------------------------

References

1 Paget's Disease of Bone: Diagnosis and Treatment. Am J Med. 2018 Nov;131(11):1298-1303.
2 Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg. 2019 Apr;32(4):331-336.
3 In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells. Arch Oral Biol. 2013 Jun;58(6):628-37.
4 Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
5 Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15;14(8):2387-95.
6 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020 May;26(Suppl 1):1-46.
7 Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)